



Evolut Clinical Guideline 3252 for Aucatzyl™ (obecabtagene autoleucel)

Guideline Number: Evolut_CG_3252	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> © 2024 - 2025 Evolut. All rights Reserved.		
Original Date: December 2024	Last Revised Date: December 2025	Implementation Date: December 2025

TABLE OF CONTENTS

STATEMENT	2
PURPOSE	2
INDICATIONS	2
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	2
CONTRAINDICATIONS/WARNINGS	2
EXCLUSION CRITERIA	3
CODING AND STANDARDS	3
CODES	3
APPLICABLE LINES OF BUSINESS	4
POLICY HISTORY	4
LEGAL AND COMPLIANCE	4
GUIDELINE APPROVAL	4
Committee	4
DISCLAIMER	4
REFERENCES	5

STATEMENT

Purpose

To define and describe the accepted indications for Aucatzyl (obecabtagene autoleucl) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Acute Lymphoblastic Leukemia (ALL)

- Aucatzyl (obecabtagene autoleucl) may be used in adult members with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
 - Cytokine release syndrome (CRS) occurred in patients receiving obecabtagene autoleucl. Do not administer obecabtagene autoleucl to patients with active infection or inflammatory disorders. Prior to administering obecabtagene autoleucl, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS.
 - Immune effector cell-associated neurotoxicity syndrome (ICANS), including fatal or life-threatening reactions, occurred in patients receiving obecabtagene autoleucl, including concurrently with CRS or after CRS resolution. Monitor for neurologic signs and symptoms after treatment with obecabtagene autoleucl. Prior to administering obecabtagene autoleucl, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage neurologic toxicities. Provide supportive care and/or corticosteroids, as needed.

- T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies.

EXCLUSION CRITERIA

- Disease progression while taking Aucatzyl (obecabtagene autoleucl).
- Concurrent use with other anticancer therapies.
- Dosing exceeds total dose of 410×10^6 CD19 chimeric antigen receptor (CAR) positive viable T cells.
- Investigational use of Aucatzyl (obecabtagene autoleucl) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of < 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- Q2058 - Obecabtagene autoleucl, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children’s Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

POLICY HISTORY

Date	Summary
December 2025	<ul style="list-style-type: none"> • Converted to new Evolent guideline template • This guideline replaces UM ONC_1513 Aucatzyl (obecabtagene autoleucel) • Updated references
December 2024	<ul style="list-style-type: none"> • New policy

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members’ health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Roddie C, et al. Obecabtagene Autoleucl in Adults with B-Cell Acute Lymphoblastic Leukemia. *N Engl J Med*. 2024 Dec 12;391(23):2219-2230. doi: 10.1056/NEJMoa2406526.
2. Aucatzyl prescribing information. Autolus Inc., Gaithersburg, MD 2025.
3. Clinical Pharmacology Elsevier Gold Standard 2025.
4. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
5. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
6. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
7. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
8. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
9. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.